GSK India Q2 FY27 Results: Revenue Rises 21% To ₹1,180 Crore And Profit After Tax Grows 31% To ₹335 Crore

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) reported revenue of ₹1,180 crore for Q2 FY27, an increase of 21% year-on-year (YoY). Profit after tax (PAT) grew 31% to ₹335 crore, and earnings before interest, tax, depreciation and amortisation (EBITDA) also increased 20%.

Profit before tax (PBT) grew both sequentially and yearly to stand at ₹460 crore. It was ₹322 crore in the previous quarter of the current financial year, and ₹354 crore in the same period last year.

The GSK India share price closed at ₹2,575.10 on 03 November, up 1.73% on the National Stock Exchange (NSE).

How Did The Company's Key Business Portfolios Perform?

The General Medicines portfolio delivered strong growth and several of the company's established brands gained market share. The company also introduced additional product formulations to address changing patient requirements.

Its Vaccines business continued to grow. It was supported by its position in the private paediatric vaccines market and efforts to expand adult vaccination awareness. The company also highlighted an increase in its shingles vaccine aimed at the elderly.

The Oncology business gained momentum during the quarter, It was also boosted by its expanding presence in the Indian market. GSK India also announced plans to enter the haemato-oncology segment with the launch of BLENREP, extending its presence in specialised cancer treatments.

What Did Management Say?

Bhushan Akshikar, Managing Director of GSK India, said the quarterly performance reflected the execution of the company's strategy to build a science-led, innovation-focused business.

Akshikar added that GSK India would continue to focus on key launches in Oncology and adult vaccination, while progressing its late-stage pipeline and simplifying its operations.

He also flagged inflationary pressures and supply-chain risks arising from the changing geopolitical environment. The company is working to strengthen supply-chain resilience through diversified sourcing, contingency planning and better visibility across operations.

Also Read - NSE Q2 FY27 Results: Consolidated Profit Rises 23% To ₹2,578 Crore As Total Income Grows 9% Year-on-Year